Girish C Shukla

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8129960/publications.pdf Version: 2024-02-01



CIDICH C SHIIKIA

#	Article	IF	CITATIONS
1	The androgen receptor messenger RNA: what do we know?. RNA Biology, 2022, 19, 819-828.	3.1	4
2	Small-Molecule HSP27 Inhibitor Abolishes Androgen Receptors in Glioblastoma. Journal of Medicinal Chemistry, 2021, 64, 1570-1583.	6.4	10
3	Regulation of cholesterol biosynthesis and lipid metabolism: A microRNA management perspective. Steroids, 2021, 173, 108878.	1.8	22
4	A narrative review on the basic and clinical aspects of the novel SARS-CoV-2, the etiologic agent of COVID-19. Annals of Translational Medicine, 2020, 8, 1686-1686.	1.7	6
5	Basal Signalling Through Death Receptor 5 and Caspase 3 Activates p38 Kinase to Regulate Serum Response Factor (SRF)-Mediated MyoD Transcription. Journal of Molecular Signaling, 2020, 14, 1.	0.5	1
6	MiR-644a Disrupts Oncogenic Transformation and Warburg Effect by Direct Modulation of Multiple Genes of Tumor-Promoting Pathways. Cancer Research, 2019, 79, 1844-1856.	0.9	35
7	Integrated analysis of miRNA landscape and cellular networking pathways in stage-specific prostate cancer. PLoS ONE, 2019, 14, e0224071.	2.5	14
8	Title is missing!. , 2019, 14, e0224071.		0
9	Title is missing!. , 2019, 14, e0224071.		0
10	RNA biology-featuring the special issue guest editors "cancer letters― Cancer Letters, 2018, 421, 41-42.	7.2	0
11	Hallmarks of cancer– focus on RNA metabolism and regulatory noncoding RNAs. Cancer Letters, 2018, 420, 208-209.	7.2	3
12	Analysis of the androgen receptor–regulated IncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nature Genetics, 2018, 50, 814-824.	21.4	196
13	MicroRNAs in prostate cancer: Functional role as biomarkers. Cancer Letters, 2017, 407, 9-20.	7.2	114
14	A comprehensive review of web-based non-coding RNA resources for cancer research. Cancer Letters, 2017, 407, 1-8.	7.2	63
15	The muscle regulatory transcription factor MyoD participates with p53 to directly increase the expression of the pro-apoptotic Bcl2 family member PUMA. Apoptosis: an International Journal on Programmed Cell Death, 2017, 22, 1532-1542.	4.9	16
16	Mutations of RNA splicing factors in hematological malignancies. Cancer Letters, 2017, 409, 1-8.	7.2	14
17	Racial disparities disruptive genes in prostate carcinogenesis. Frontiers in Bioscience - Scholar, 2017, 9, 244-253.	2.1	8
18	Aging and calorie restriction regulate the expression of miR-125a-5p and its target genes Stat3, Casp2 and Stard13. Aging, 2017, 9, 1825-1843.	3.1	39

GIRISH C SHUKLA

#	Article	IF	CITATIONS
19	Androgen receptorâ€related diseases: what do we know?. Andrology, 2016, 4, 366-381.	3.5	70
20	Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3′-untranslated region. Prostate, 2016, 76, 834-844.	2.3	4
21	U6atac snRNA stem-loop interacts with U12 p65 RNA binding protein and is functionally interchangeable with the U12 apical stem-loop III. Scientific Reports, 2016, 6, 31393.	3.3	8
22	Deep sequencing of small RNA libraries from human prostate epithelial and stromal cells reveal distinct pattern of microRNAs primarily predicted to target growth factors. Cancer Letters, 2016, 371, 262-273.	7.2	5
23	miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies. Molecular Cancer, 2015, 14, 185.	19.2	42
24	MicroRNA Regulating Glutathione S-Transferase P1 in Prostate Cancer. Current Pharmacology Reports, 2015, 1, 79-88.	3.0	16
25	Targeting of Androgen Receptor Expression by Andro-miRs as Novel Adjunctive Therapeutics in Prostate Cancer. Journal of Cancer Therapy, 2013, 04, 47-58.	0.4	3
26	Housekeeping Gene Selection Advisory: Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) and β-Actin Are Targets of miR-644a. PLoS ONE, 2012, 7, e47510.	2.5	71
27	miR 488* inhibits androgen receptor expression in prostate carcinoma cells. International Journal of Cancer, 2011, 129, 810-819.	5.1	113
28	Functionally important structural elements of U12 snRNA. Nucleic Acids Research, 2011, 39, 8531-8543.	14.5	18
29	MicroRNAs and Androgen Receptor 3' Untranslated Region: A Missing Link in Castration-resistant Prostate Cancer?. Molecular and Cellular Pharmacology, 2011, 3, 107-113.	1.7	8
30	MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Molecular and Cellular Pharmacology, 2011, 3, 83-92.	1.7	650
31	The conserved 3' end domain of U6atac snRNA can direct U6 snRNA to the minor spliceosome. Rna, 2009, 15, 1198-1207.	3.5	7
32	Intrinsic expression of host genes and intronic miRNAs in prostate carcinoma cells. Cancer Cell International, 2009, 9, 21.	4.1	35
33	U4 small nuclear RNA can function in both the major and minor spliceosomes. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 93-98.	7.1	14
34	Domains of human U4atac snRNA required for U12-dependent splicing in vivo. Nucleic Acids Research, 2002, 30, 4650-4657.	14.5	26
35	A Catalytically Active Group II Intron Domain 5 Can Function in the U12-Dependent Spliceosome. Molecular Cell, 2002, 9, 1145-1150.	9.7	69
36	A revised model for U4atac/U6atac snRNA base pairing. Rna, 2002, 8, 125-128.	3.5	18

GIRISH C SHUKLA

#	ARTICLE	IF	CITATIONS
37	The intramolecular stem-loop structure of U6 snRNA can functionally replace the U6atac snRNA stem-loop. Rna, 2001, 7, 94-105.	3.5	25
38	Conservation of functional features of U6atac and U12 snRNAs between vertebrates and higher plants. Rna, 1999, 5, 525-538.	3.5	57
39	Immunological characteristics of a recombinant hepatitis B virus-derived multiple-epitope polypeptide: a study in polyvalent vaccine design. Vaccine, 1994, 12, 259-266.	3.8	15